Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.
설문조사
2/5 보강
OpenAlex 토픽 ·
Psychedelics and Drug Studies
Cannabis and Cannabinoid Research
Forensic Toxicology and Drug Analysis
[PURPOSE] To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S.
- 표본수 (n) 42,815
- p-value p < 0.01
- 95% CI 40.0-43.2
APA
Amrit Baral, Yue Pan, et al. (2026). Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.. Cancer causes & control : CCC, 37(6). https://doi.org/10.1007/s10552-026-02172-x
MLA
Amrit Baral, et al.. "Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.." Cancer causes & control : CCC, vol. 37, no. 6, 2026.
PMID
42017992 ↗
Abstract 한글 요약
[PURPOSE] To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors.
[METHODS] We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n = 42,815 for 2015-2019; n = 21,144 for 2021-2022). Lifetime cannabis and classic psychedelic (LSD, psilocybin, peyote/mescaline) use and cancer history (physician-diagnosed, self-reported) were assessed. Weighted prevalence estimates and 95% CIs were computed, and subgroup analyses by cancer type/site were conducted.
[RESULTS] Between 2015 and 2019, cannabis use was similar among cancer survivors (41.6%, 95% CI 40.0-43.2) and individuals without cancer (42.6%, 95% CI 42.0-43.2, p = 0.21). LSD (8.9, 95% CI 8.1-9.7 vs 10.3, 95% CI 9.8-10.8) and psilocybin (6.4, 95% CI 5.6-7.3 vs 7.7, 95% CI 7.4-8.1) were lower among cancer survivors. Any classic psychedelic use was 11.6% (95% CI 10.6-12.5) among cancer survivors versus 12.9% (95% CI 12.4-13.3) among those without cancer (p < 0.01). Lifetime use of both cannabis and classic psychedelics was lower in cancer survivors (11.2%, 95% CI 10.3-12.1) than in individuals without cancer (12.6%, 95% CI 12.2-13.1, p < 0.01). Between 2021 and 2022, overall group differences were not statistically significant. Across both periods, prevalence varied by cancer type/site, with head and neck, cervical, and hepatobiliary/pancreatic cancer survivors having the highest co-use.
[CONCLUSION] Lifetime cannabis, classic psychedelic, and co-use patterns showed modest differences by cancer history and meaningful variation across cancer type/site. Overall, these findings suggest that substance use patterns among cancer survivors are not uniform and may differ across survivor subgroups.
[METHODS] We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n = 42,815 for 2015-2019; n = 21,144 for 2021-2022). Lifetime cannabis and classic psychedelic (LSD, psilocybin, peyote/mescaline) use and cancer history (physician-diagnosed, self-reported) were assessed. Weighted prevalence estimates and 95% CIs were computed, and subgroup analyses by cancer type/site were conducted.
[RESULTS] Between 2015 and 2019, cannabis use was similar among cancer survivors (41.6%, 95% CI 40.0-43.2) and individuals without cancer (42.6%, 95% CI 42.0-43.2, p = 0.21). LSD (8.9, 95% CI 8.1-9.7 vs 10.3, 95% CI 9.8-10.8) and psilocybin (6.4, 95% CI 5.6-7.3 vs 7.7, 95% CI 7.4-8.1) were lower among cancer survivors. Any classic psychedelic use was 11.6% (95% CI 10.6-12.5) among cancer survivors versus 12.9% (95% CI 12.4-13.3) among those without cancer (p < 0.01). Lifetime use of both cannabis and classic psychedelics was lower in cancer survivors (11.2%, 95% CI 10.3-12.1) than in individuals without cancer (12.6%, 95% CI 12.2-13.1, p < 0.01). Between 2021 and 2022, overall group differences were not statistically significant. Across both periods, prevalence varied by cancer type/site, with head and neck, cervical, and hepatobiliary/pancreatic cancer survivors having the highest co-use.
[CONCLUSION] Lifetime cannabis, classic psychedelic, and co-use patterns showed modest differences by cancer history and meaningful variation across cancer type/site. Overall, these findings suggest that substance use patterns among cancer survivors are not uniform and may differ across survivor subgroups.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.